WHO
REGULATORY UPDATE
First Isoniazid/Moxifloxacin (hydrochloride)/Rifapentine FDC tablet product prequalified
Published: 10/29/2026Detected: 9/28/2026
Summary preview
Adds WHO Prequalification (PQT) listing for a fixed-dose combination (FDC) tablet containing isoniazid/moxifloxacin (hydrochloride)/rifapentine (TB415) from Lupin (India), marking a first-of-its-kind prequalified…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
manufacturing
quality
clinical
safety
labeling
#WHO prequalification
#TB415
#fixed-dose combination
#isoniazid
#moxifloxacin hydrochloride
Official Source Document Source Verified
Access the original document directly from WHO.